Phase i study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 2, 2009, Pages 287-295

  Mita, Monica ^b   Mita, Alain ^b   Sarantopoulos, John ^b   Takimoto, Chris H ^b   Rowinsky, Eric K ^b   Romero, Ofelia ^b   Angiuli, Patrizia ^c,d   Allievi, Cecilia ^d   Eisenfeld, Amy ^d   Verschraegen, Claire F ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b San Antonio Cancer Institute   (United States)

^c Cell Therapeutics Inc   (Italy)

^d Cell Therapeutics Inc   (United States)

Author keywords

Clinical trials; Paclitaxel; Paclitaxel poliglumex; Pharmacodynamics; Pharmacokinetics; Phase I; PPX; Solid tumors

Indexed keywords

PACLITAXEL POLIGLUMEX; PPX; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST TUMOR; CARCINOID; CLINICAL ARTICLE; CLINICAL TRIAL; COLON TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ESOPHAGUS TUMOR; FATIGUE; FEMALE; HEAD AND NECK TUMOR; HUMAN; HYPOTENSION; KIDNEY TUMOR; LIMB PAIN; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVARY TUMOR; PANCREAS TUMOR; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE TUMOR; RECOMMENDED DRUG DOSE; SOLID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PACLITAXEL; POLYGLUTAMIC ACID; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 67349223892     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0869-5     Document Type: Article

References (21)

1. A Sparreboom L van Zuylen E Brouwer WJ Loos P de Bruijn H Gelderblom M Pillay K Nooter G Stoter J Verweij 1999 Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications Cancer Res 59 1454 1457 (Pubitemid 29160110)
2. NK Ibrahim N Desai S Legha P Soon-Shiong RL Theriault E Rivera B Esmaeli SE Ring A Bedikian GN Hortobagyi JA Ellerhorst 2002 Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel Clin Cancer Res 8 1038 1044 (Pubitemid 34517637)
3. TY Kim DW Kim JY Chung SG Shin SC Kim DS Heo NK Kim YJ Bang 2004 Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies Clin Cancer Res 10 3708 3716 (Pubitemid 38697604)
4. NV Koshkina JC Waldrep LE Roberts E Golunski S Melton V Knight 2001 Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model Clin Cancer Res 7 3258 3262 (Pubitemid 32963851)
5. JM Terwogt B Nuijen WW Huinink JH Beijnen 1997 Alternative formulations of paclitaxel Cancer Treat Rev 23 87 95 (Pubitemid 27317514)
6. C Li DF Yu RA Newman F Cabral LC Stephens N Hunter L Milas S Wallace 1998 Complete regression of well-established tumors using a novel water-soluble poly(l-glutamic acid)-paclitaxel conjugate Cancer Res 58 2404 2409 (Pubitemid 28252701)
7. KD Jensen A Nori M Tijerina P Kopeckova J Kopecek 2003 Cytoplasmic delivery and nuclear targeting of synthetic macromolecules J Control Release 87 89 105 (Pubitemid 36258389)
8. K Greish J Fang T Inutsuka A Nagamitsu H Maeda 2003 Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting Clin Pharmacokinet 42 1089 1105 (Pubitemid 37357647)
9. Y Matsumura H Maeda 1986 A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res 46 6387 6392 (Pubitemid 17221789)
10. C Li JE Price L Milas NR Hunter S Ke DF Yu C Charnsangavej S Wallace 1999 Antitumor activity of poly(l-glutamic acid)-paclitaxel on syngeneic and xenografted tumors Clin Cancer Res 5 891 897 (Pubitemid 29180842)
11. AV Boddy ER Plummer R Todd J Sludden M Griffin L Robson J Cassidy D Bissett A Bernareggi MW Verrill AH Calvert 2005 A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules Clin Cancer Res 11 7834 7840 (Pubitemid 41611628)
12. ML Veronese K Flaherty A Kramer BA Konkle M Morgan JP Stevenson PJ O'Dwyer 2005 Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors Cancer Chemother Pharmacol 55 497 501 (Pubitemid 40568981)
13. L Gianni CM Kearns A Giani G Capri L Vigano A Lacatelli G Bonadonna MJ Egorin 1995 Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans J Clin Oncol 13 180 190
14. S Mielke A Sparreboom K Mross 2006 Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes Eur J Cancer 42 24 30 (Pubitemid 41814529)
15. MC Green AU Buzdar T Smith NK Ibrahim V Valero MF Rosales M Cristofanilli DJ Booser L Pusztai E Rivera RL Theriault C Carter 2005 Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks J Clin Oncol 23 5983 5992 (Pubitemid 46300215)
16. EJ Freireich EA Gehan DP Rall LH Schmidt HE Skipper 1966 Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man Cancer Chemother Rep 50 219 244
17. B Davies T Morris 1993 Physiological parameters in laboratory animals and humans Pharm Res 10 1093 1095 (Pubitemid 23211439)
18. T Dipetrillo L Milas D Evans P Akerman T Ng T Miner D Cruff B Chauhan D Iannitti D Harrington H Safran 2006 Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study Am J Clin Oncol 29 376 379 (Pubitemid 44197542)
19. D Fennelly C Aghajanian F Shapiro C O'Flaherty M McKenzie C O'Connor W Tong L Norton D Spriggs 1997 Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer J Clin Oncol 15 187 192 (Pubitemid 27020572)
20. W Akerley JE Herndon MJ Egorin AP Lyss HL Kindler DM Savarese CA Sherman DM Rosen D Hollis MJ Ratain MR Green 2003 Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the cancer and leukemia group B Cancer 97 2480 2486 (Pubitemid 36542487)
21. AD Seidman D Berry C Cirrincione L Harris H Muss PK Marcom G Gipson H Burstein D Lake CL Shapiro P Ungaro L Norton 2008 Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 non-overexpressors: final results of Cancer and Leukemia Group B protocol 9840 J Clin Oncol 26 1642 1649